Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic people
- Francesco Panero, MD1,
- Giulia Novelli, MD1,
- Chiara Zucco, MD1,
- Paolo Fornengo, MD1,
- Massimo Perotto, MD1,
- Olivia Segre, MD1,
- Giorgio Grassi, MD2,
- Paolo Cavallo-Perin, MD1 and
- Graziella Bruno, MD (graziella.bruno{at}unito.it)1
- 1Department of Internal Medicine, University of Turin, Italy
- 2Diabetes Unit, S. Giovanni Battista Hospital, Turin, Italy
Abstract
Objective: A protective effect of residual β-cell function on microvascular complications of type 1 diabetes has been suggested. Our aim was to retrospectively evaluate the association between fasting plasma C-peptide values and micro- and macrovascular complications.
Research design and methods: We recruited a clinic-based cohort of 471 type 1 diabetic persons, born after 1945 and cared for in period 1994-2004. Centralized measurements and standardized procedures of ascertainment of micro- and macrovascular complications were employed. Individual cumulative average of HbA1c up to 2007 was calculated.
Results: a residual β-cell secretion was detected even many years after diabetes diagnosis. In multivariate linear regression analysis, fasting plasma C-peptide values were positively associated with age at diagnosis (β=0.02, p<0.0001) and triglycerides (β =0.20, p=0.05), and inversely associated with diabetes duration (β=−0.03, p<0.0001), and HDL-cholesterol (β =−0.006, p=0.03). The final model explained 21% of fasting C-peptide variability. With respect to fasting C-peptide values in the lowest tertile (< 0.06 nmol/l), higher values were associated with lower prevalence of microvascular complications (OR=0.59, 95% CI 0.37–0.94), independently of age, sex, diabetes duration, individual cumulative HbA1c average during the study period, hypertension, and cardiovascular diseases. No association was evident with macrovascular complications (OR=0.77, 95% CI 0.38–1.58).
Conclusions: Our study shows an independent protective effect of residual β-cell function on the development of microvascular complications in type 1 diabetes, suggesting the potential beneficial effect of treatment allowing the preservation of even modest β-cell function over time.
Footnotes
-
- Received July 7, 2008.
- Accepted November 7, 2008.
- Copyright © American Diabetes Association














